Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treat…
$6.36+2.91%
报价 2026-11-06
市值
$951.7M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -46.4%
$6.18$11.87
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | $951.7M | +2.9% | – | 100% | – | – | – | |
| SVRASavara Inc. | $992.4M | +10.3% | +307.1% | 0% | – | – | – | |
| ANROAlto Neuroscience, Inc. | $987.3M | +15.0% | – | 0% | – | – | – | |
| MLTXMoonLake Immunotherapeutics | $981.3M | +6.8% | – | 0% | – | – | – | |
| JBIOJade Biosciences, Inc. | $958.4M | +6.9% | – | 0% | – | – | – | |
| SLNSilence Therapeutics plc | $931.9M | +0.1% | – | 51% | – | – | – | |
| ODTXOdyssey Therapeutics, Inc. | $924.2M | +1.9% | – | 0% | – | – | – | |
| ORICORIC Pharmaceuticals, Inc. | $914.2M | +3.9% | – | 0% | – | – | – | |
| GLUEMonte Rosa Therapeutics, Inc. | $901.8M | +3.1% | -67.4% | 95.3% | – | – | – | |
| 同行中位数 | – | – | +119.9% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 EUR（非美元）暂无季度数据（首次研究运行后填充）。